<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00135330</url>
  </required_header>
  <id_info>
    <org_study_id>H8O-US-GWAY</org_study_id>
    <nct_id>NCT00135330</nct_id>
  </id_info>
  <brief_title>An Evaluation of Exenatide and Rosiglitazone in Subjects With Type 2 Diabetes Mellitus</brief_title>
  <official_title>An Evaluation of the Metabolic Effects of Exenatide, Rosiglitazone, and Exenatide Plus Rosiglitazone in Subjects With Type 2 Diabetes Mellitus Treated With Metformin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This protocol is designed to evaluate the metabolic effects of adding exenatide,
      rosiglitazone, or both to an existing regimen of metformin in subjects with inadequate
      glycemic control.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2005</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in ASIiAUC During a Hyperglycemic Clamp Test.</measure>
    <time_frame>20 weeks</time_frame>
    <description>Change in insulin incremental area under the concentration-time curve (ASIiAUC) from baseline to week 20. ASIiAUC is a measure of beta-cell function.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in AUC for Glucose During a Meal Challenge Test (MCT).</measure>
    <time_frame>Week 20</time_frame>
    <description>Change in AUC(15-180 min) for glucose during a MCT baseline to week 20.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Insulin Sensitivity Index as Measured by M-value.</measure>
    <time_frame>Week 20</time_frame>
    <description>Change of M-Value (mg/kg-min) during hyperinsulinemic euglycemic clamp test from baseline to week 20.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Insulin AUC in the First Stage From Baseline to Endpoint.</measure>
    <time_frame>Week 20</time_frame>
    <description>Change in insulin AUC in the first stage(uIU-min/ml) from baseline to week 20. &quot;First stage&quot; represents the first 10 minutes after reaching a steady state during a hyperglycemic clamp test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Insulin iAUC From Baseline to Endpoint.</measure>
    <time_frame>Week 20</time_frame>
    <description>Change in insulin iAUC in the first stage(uIU-min/ml) from baseline to week 20. &quot;First stage&quot; represents the first 10 minutes after reaching a steady state during a hyperglycemic clamp test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio (Value at Endpoint Divided by Value at Baseline) of AUC for Insulin During a Meal Challenge Test (MCT).</measure>
    <time_frame>Week 20</time_frame>
    <description>Ratio (value at endpoint divided by value at baseline) of AUC (15-180 min) for insulin (uIU-min/ml) during MCT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in AUC for C-peptide During a Meal Challenge Test (MCT).</measure>
    <time_frame>Week 20</time_frame>
    <description>Ratio (value at endpoint divided by value at baseline) of AUC(15-180 min) for C-peptide (nmol-min/L) during a MCT from baseline to week 20.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Incremental for Postprandial Glucose During a Meal Challenge Test (MCT).</measure>
    <time_frame>Week 20</time_frame>
    <description>Change in incremental for postprandial glucose (mmol/L) during a MCT from baseline to week 20.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Incremental for Postprandial Insulin During Meal Challenge Test (MCT).</measure>
    <time_frame>Week 20</time_frame>
    <description>Change in incremental for postprandial insulin (mmol/L) during meal challenge test (MCT) from baseline to week 20.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Incremental for Postprandial C-peptide During Meal Challenge Test (MCT).</measure>
    <time_frame>Week 20</time_frame>
    <description>Change in incremental for postprandial C-peptide (mmol/L) during MCT from baseline to week 20.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HbA1c</measure>
    <time_frame>Week 20</time_frame>
    <description>Change in HbA1c from baseline to week 20.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting Serum Glucose Concentration.</measure>
    <time_frame>Week 20</time_frame>
    <description>Change in fasting serum glucose concentration from baseline to week 20.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting C-peptide</measure>
    <time_frame>Week 20</time_frame>
    <description>Change in fasting C-peptide from baseline to week 20.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting Insulin</measure>
    <time_frame>Week 20</time_frame>
    <description>Change in fasting insulin from baseline to week 20.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting Proinsulin</measure>
    <time_frame>Week 20</time_frame>
    <description>Ratio (endpoint value divided by baseline value) for fasting proinsulin, comparing endpoint (week 20) to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Body Weight</measure>
    <time_frame>Week 20</time_frame>
    <description>Change in body weight from baseline to week 20.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting Total Cholesterol.</measure>
    <time_frame>Week 20</time_frame>
    <description>Change in fasting total cholestrol from baseline to week 20.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting HDL Cholesterol</measure>
    <time_frame>Week 20</time_frame>
    <description>Change in fasting high-density lipoprotein (HDL) cholesterol from baseline to week 20.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting LDL Cholesterol</measure>
    <time_frame>Week 20</time_frame>
    <description>Change in fasting low-density lipoprotein (LDL) cholesterol from baseline to week 20.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting Triglycerides</measure>
    <time_frame>Week 20</time_frame>
    <description>Ratio (endpint value divided by baseline value) of fasting triglycerides from baseline to week 20.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Percent Body Fat During a Meal Challenge Test (MCT)</measure>
    <time_frame>20 weeks</time_frame>
    <description>Change in percent body fat from baseline to week 20, as assessed during an MCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Body Fat Mass During a Meal Challenge Test (MCT)</measure>
    <time_frame>20 weeks</time_frame>
    <description>Change in body fat mass form baseline to week 20, as assessed during an MCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Lean Body Mass During a Meal Challenge Test (MCT)</measure>
    <time_frame>20 weeks</time_frame>
    <description>Change in lean body mass from baseline to week 20, as assessed during an MCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Waist Circumference</measure>
    <time_frame>20 weeks</time_frame>
    <description>Change in waist circumference from baseline to week 20</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Hip Circumference</measure>
    <time_frame>20 weeks</time_frame>
    <description>Change in hip circumference form baseline to week 20</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Waist-to-hip Ratio</measure>
    <time_frame>20 weeks</time_frame>
    <description>Change in waist-to-hip ratio (waist circumference divided by hip circumference) from baseline to week 20</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Hypoglycemia Events</measure>
    <time_frame>20 weeks</time_frame>
    <description>Number of subjects experiencing hypoglycemia at any point during the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypoglycemia Rate Per 30 Days Per Patient</measure>
    <time_frame>20 weeks</time_frame>
    <description>Average number of episodes of hypoglycemia per 30 days per patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pedal Edema Score</measure>
    <time_frame>20 weeks</time_frame>
    <description>Pedal edema scores experienced by each patient throughout the study (&quot;1+&quot; indicates a patient experienced a pedal edema score of 1 , 2, or 3; &quot;2+&quot; indicates a patient experienced a pedal edema score of 2 or 3, etc.)
Scale:
Slight pitting, no visible distortion, disappears rapidly
A somewhat deeper pit than in 1+, but again no readily detectable distortion, and it disappears in 10 - 15 seconds
The pit is noticeably deep and may last more than a minute; the dependent extremity looks fuller and swollen
The pit is very deep, lasts as long as 2 - 5 minutes, and the dependent extremity is grossly distorted</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">137</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Exenatide Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Exenatide plus Rosiglitazone Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Rosiglitazone Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>exenatide</intervention_name>
    <description>subcutaneous injection, 5mcg or 10mcg, twice a day</description>
    <arm_group_label>Exenatide Arm</arm_group_label>
    <arm_group_label>Exenatide plus Rosiglitazone Arm</arm_group_label>
    <other_name>Byetta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rosiglitazone</intervention_name>
    <description>oral tablet, 2mg or 4mg, twice a day</description>
    <arm_group_label>Exenatide plus Rosiglitazone Arm</arm_group_label>
    <arm_group_label>Rosiglitazone Arm</arm_group_label>
    <other_name>Avandia</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HbA1c of 6.8% to 10.0%, inclusive.

          -  Body mass index (BMI) of 25 kg/m^2 to 40 kg/m^2, inclusive.

        Exclusion Criteria:

          -  Have participated in this study previously, or have received exenatide, pramlintide
             acetate, GLP-1 analogs, or dipeptidyl peptidase-IV (DPP-IV) inhibitors

          -  Have participated in an interventional, medical, surgical, or pharmaceutical study (a
             study in which an experimental, drug, medical, or surgical treatment was given) within
             30 days of study start. This criterion includes drugs that have not received
             regulatory approval for any indication at the time of study start.

          -  Treated with any of the following medications:

               -  Thiazolidinedione within 5 months of screening;

               -  Sulfonylurea within 3 months of screening;

               -  Metformin/sulfonylurea combination therapy within 3 months of screening;

               -  Alpha-glucosidase inhibitor within 3 months of screening;

               -  Meglitinide within 3 months of screening;

               -  Insulin for more than 1 week within the 3 months prior to screening.

               -  Symlin (pramlintide acetate) injection or Byetta (exenatide) injection at any
                  time

               -  Chronic (more than 2 weeks) or recent (within 4 weeks of study start) use of a
                  drug that directly affects gastrointestinal motility

               -  Are receiving chronic (lasting longer than 2 weeks) systemic glucocorticoid
                  therapy (excluding topical and inhaled preparations) or have received such
                  therapy within the 4 weeks immediately preceding study start

               -  Regular use of a medication with addictive potential such as an opiate, narcotic,
                  or tranquilizer

               -  Systemic antineoplastic agent

               -  Systemic transplantation medication

               -  Drugs for weight loss, including over-the-counter medications, within the 4
                  months prior to study start
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Malone, MD</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pittsfield</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cincinatti</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>League City</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New Braunfels</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Renton</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 24, 2005</study_first_submitted>
  <study_first_submitted_qc>August 24, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2005</study_first_posted>
  <results_first_submitted>July 21, 2009</results_first_submitted>
  <results_first_submitted_qc>July 21, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 28, 2009</results_first_posted>
  <last_update_submitted>March 19, 2015</last_update_submitted>
  <last_update_submitted_qc>March 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 7, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>diabetes</keyword>
  <keyword>exenatide</keyword>
  <keyword>rosiglitazone</keyword>
  <keyword>Amylin</keyword>
  <keyword>Lilly</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Exenatide</mesh_term>
    <mesh_term>Rosiglitazone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Enrollment occurred between 18 October 2005 and 14 March 2008.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Exenatide</title>
          <description>Exenatide 5 mcg twice a day (BID) for 4-weeks followed by exenatide 10 mcg BID for 16-weeks.</description>
        </group>
        <group group_id="P2">
          <title>Exenatide Plus Rosiglitazone</title>
          <description>Exenatide 5 mcg BID + rosiglitazone 2 mg BID for 4-weeks followed by exenatide 10 mcg + rosiglitazone 4 mg BID for 16-weeks.</description>
        </group>
        <group group_id="P3">
          <title>Rosiglitazone</title>
          <description>Rosiglitazone 2 mg BID for 4-weeks followed by rosiglitazone 4 mgs BID for 16-weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="47"/>
                <participants group_id="P3" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="34"/>
                <participants group_id="P3" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient Decision</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Exenatide</title>
          <description>Exenatide 5 mcg twice a day (BID) for 4-weeks followed by exenatide 10 mcg BID for 16-weeks.</description>
        </group>
        <group group_id="B2">
          <title>Exenatide Plus Rosiglitazone</title>
          <description>Exenatide 5 mcg BID + rosiglitazone 2 mg BID for 4-weeks followed by exenatide 10 mcg + rosiglitazone 4 mg BID for 16-weeks.</description>
        </group>
        <group group_id="B3">
          <title>Rosiglitazone</title>
          <description>Rosiglitazone 2 mg BID for 4-weeks followed by rosiglitazone 4 mgs BID for 16-weeks.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="45"/>
            <count group_id="B2" value="47"/>
            <count group_id="B3" value="45"/>
            <count group_id="B4" value="137"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="36"/>
                    <measurement group_id="B4" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.99" spread="9.71"/>
                    <measurement group_id="B2" value="54.63" spread="9.91"/>
                    <measurement group_id="B3" value="55.54" spread="10.71"/>
                    <measurement group_id="B4" value="55.70" spread="10.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in ASIiAUC During a Hyperglycemic Clamp Test.</title>
        <description>Change in insulin incremental area under the concentration-time curve (ASIiAUC) from baseline to week 20. ASIiAUC is a measure of beta-cell function.</description>
        <time_frame>20 weeks</time_frame>
        <population>All patients in full analysis set who participated in clamp test and have both baseline and endpoint measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Exenatide</title>
            <description>Exenatide 5 mcg twice a day (BID) for 4-weeks followed by exenatide 10 mcg BID for 16-weeks.</description>
          </group>
          <group group_id="O2">
            <title>Exenatide Plus Rosiglitazone</title>
            <description>Exenatide 5 mcg BID + rosiglitazone 2 mg BID for 4-weeks followed by exenatide 10 mcg + rosiglitazone 4 mg BID for 16-weeks.</description>
          </group>
          <group group_id="O3">
            <title>Rosiglitazone</title>
            <description>Rosiglitazone 2 mg BID for 4-weeks followed by rosiglitazone 4 mgs BID for 16-weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in ASIiAUC During a Hyperglycemic Clamp Test.</title>
          <description>Change in insulin incremental area under the concentration-time curve (ASIiAUC) from baseline to week 20. ASIiAUC is a measure of beta-cell function.</description>
          <population>All patients in full analysis set who participated in clamp test and have both baseline and endpoint measurement.</population>
          <units>uIU-min/ml</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline ASIiAUC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="643.40" spread="106.71"/>
                    <measurement group_id="O2" value="686.41" spread="103.70"/>
                    <measurement group_id="O3" value="786.12" spread="113.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in ASIiAUC at week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="747.26" spread="187.40"/>
                    <measurement group_id="O2" value="194.68" spread="181.59"/>
                    <measurement group_id="O3" value="-99.85" spread="200.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The ratio of the ASI-iAUC at Week 20 to that at baseline was compared between the treatment groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.282</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in AUC for Glucose During a Meal Challenge Test (MCT).</title>
        <description>Change in AUC(15-180 min) for glucose during a MCT baseline to week 20.</description>
        <time_frame>Week 20</time_frame>
        <population>All patients in full analysis set who have both baseline and endpoint measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Exenatide</title>
            <description>Exenatide 5 mcg twice a day (BID) for 4-weeks followed by exenatide 10 mcg BID for 16-weeks.</description>
          </group>
          <group group_id="O2">
            <title>Exenatide Plus Rosiglitazone</title>
            <description>Exenatide 5 mcg BID + rosiglitazone 2 mg BID for 4-weeks followed by exenatide 10 mcg + rosiglitazone 4 mg BID for 16-weeks.</description>
          </group>
          <group group_id="O3">
            <title>Rosiglitazone</title>
            <description>Rosiglitazone 2 mg BID for 4-weeks followed by rosiglitazone 4 mgs BID for 16-weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in AUC for Glucose During a Meal Challenge Test (MCT).</title>
          <description>Change in AUC(15-180 min) for glucose during a MCT baseline to week 20.</description>
          <population>All patients in full analysis set who have both baseline and endpoint measurement.</population>
          <units>mmol-min/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline glucose AUC during MCT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1782.86" spread="60.47"/>
                    <measurement group_id="O2" value="1799.68" spread="59.60"/>
                    <measurement group_id="O3" value="1741.87" spread="60.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in glucose AUC during MCT at week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-560.12" spread="50.95"/>
                    <measurement group_id="O2" value="-635.24" spread="50.25"/>
                    <measurement group_id="O3" value="-425.59" spread="51.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Insulin Sensitivity Index as Measured by M-value.</title>
        <description>Change of M-Value (mg/kg-min) during hyperinsulinemic euglycemic clamp test from baseline to week 20.</description>
        <time_frame>Week 20</time_frame>
        <population>All patients in full analysis set who participated in clamp test and have both baseline and endpoint measurements.</population>
        <group_list>
          <group group_id="O1">
            <title>Exenatide</title>
            <description>Exenatide 5 mcg twice a day (BID) for 4-weeks followed by exenatide 10 mcg BID for 16-weeks.</description>
          </group>
          <group group_id="O2">
            <title>Exenatide Plus Rosiglitazone</title>
            <description>Exenatide 5 mcg BID + rosiglitazone 2 mg BID for 4-weeks followed by exenatide 10 mcg + rosiglitazone 4 mg BID for 16-weeks.</description>
          </group>
          <group group_id="O3">
            <title>Rosiglitazone</title>
            <description>Rosiglitazone 2 mg BID for 4-weeks followed by rosiglitazone 4 mgs BID for 16-weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Insulin Sensitivity Index as Measured by M-value.</title>
          <description>Change of M-Value (mg/kg-min) during hyperinsulinemic euglycemic clamp test from baseline to week 20.</description>
          <population>All patients in full analysis set who participated in clamp test and have both baseline and endpoint measurements.</population>
          <units>mg/kg-min</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>M-Value at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.89" spread="0.495"/>
                    <measurement group_id="O2" value="2.49" spread="0.495"/>
                    <measurement group_id="O3" value="4.02" spread="0.511"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in M-Value from baseline at week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.477" spread="0.425"/>
                    <measurement group_id="O2" value="2.07" spread="0.440"/>
                    <measurement group_id="O3" value="1.42" spread="0.442"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.308</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Insulin AUC in the First Stage From Baseline to Endpoint.</title>
        <description>Change in insulin AUC in the first stage(uIU-min/ml) from baseline to week 20. &quot;First stage&quot; represents the first 10 minutes after reaching a steady state during a hyperglycemic clamp test.</description>
        <time_frame>Week 20</time_frame>
        <population>All patients in full analysis set who participated in clamp tests and have both baseline and endpoint</population>
        <group_list>
          <group group_id="O1">
            <title>Exenatide</title>
            <description>Exenatide 5 mcg twice a day (BID) for 4-weeks followed by exenatide 10 mcg BID for 16-weeks.</description>
          </group>
          <group group_id="O2">
            <title>Exenatide Plus Rosiglitazone</title>
            <description>Exenatide 5 mcg BID + rosiglitazone 2 mg BID for 4-weeks followed by exenatide 10 mcg + rosiglitazone 4 mg BID for 16-weeks.</description>
          </group>
          <group group_id="O3">
            <title>Rosiglitazone</title>
            <description>Rosiglitazone 2 mg BID for 4-weeks followed by rosiglitazone 4 mgs BID for 16-weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Insulin AUC in the First Stage From Baseline to Endpoint.</title>
          <description>Change in insulin AUC in the first stage(uIU-min/ml) from baseline to week 20. &quot;First stage&quot; represents the first 10 minutes after reaching a steady state during a hyperglycemic clamp test.</description>
          <population>All patients in full analysis set who participated in clamp tests and have both baseline and endpoint</population>
          <units>uIU-min/ml</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline insulin AUC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="200.50" spread="50.40"/>
                    <measurement group_id="O2" value="136.84" spread="50.40"/>
                    <measurement group_id="O3" value="157.49" spread="53.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline insulin AUC at week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="134.88" spread="31.71"/>
                    <measurement group_id="O2" value="32.12" spread="31.65"/>
                    <measurement group_id="O3" value="-50.81" spread="33.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.079</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Insulin iAUC From Baseline to Endpoint.</title>
        <description>Change in insulin iAUC in the first stage(uIU-min/ml) from baseline to week 20. &quot;First stage&quot; represents the first 10 minutes after reaching a steady state during a hyperglycemic clamp test.</description>
        <time_frame>Week 20</time_frame>
        <population>All patients in full analysis set who participated in clamp tests and have both baseline and endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Exenatide</title>
            <description>Exenatide 5 mcg twice a day (BID) for 4-weeks followed by exenatide 10 mcg BID for 16-weeks.</description>
          </group>
          <group group_id="O2">
            <title>Exenatide Plus Rosiglitazone</title>
            <description>Exenatide 5 mcg BID + rosiglitazone 2 mg BID for 4-weeks followed by exenatide 10 mcg + rosiglitazone 4 mg BID for 16-weeks.</description>
          </group>
          <group group_id="O3">
            <title>Rosiglitazone</title>
            <description>Rosiglitazone 2 mg BID for 4-weeks followed by rosiglitazone 4 mgs BID for 16-weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Insulin iAUC From Baseline to Endpoint.</title>
          <description>Change in insulin iAUC in the first stage(uIU-min/ml) from baseline to week 20. &quot;First stage&quot; represents the first 10 minutes after reaching a steady state during a hyperglycemic clamp test.</description>
          <population>All patients in full analysis set who participated in clamp tests and have both baseline and endpoint.</population>
          <units>uIU-min/ml</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline insulin iAUC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.98" spread="14.29"/>
                    <measurement group_id="O2" value="-9.92" spread="14.29"/>
                    <measurement group_id="O3" value="23.09" spread="15.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline insulin iAUC at week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.08" spread="24.23"/>
                    <measurement group_id="O2" value="53.71" spread="24.54"/>
                    <measurement group_id="O3" value="11.51" spread="26.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.252</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ratio (Value at Endpoint Divided by Value at Baseline) of AUC for Insulin During a Meal Challenge Test (MCT).</title>
        <description>Ratio (value at endpoint divided by value at baseline) of AUC (15-180 min) for insulin (uIU-min/ml) during MCT.</description>
        <time_frame>Week 20</time_frame>
        <population>All patients in full analysis set who have both baseline and endpoint measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Exenatide</title>
            <description>Exenatide 5 mcg twice a day (BID) for 4-weeks followed by exenatide 10 mcg BID for 16-weeks.</description>
          </group>
          <group group_id="O2">
            <title>Exenatide Plus Rosiglitazone</title>
            <description>Exenatide 5 mcg BID + rosiglitazone 2 mg BID for 4-weeks followed by exenatide 10 mcg + rosiglitazone 4 mg BID for 16-weeks.</description>
          </group>
          <group group_id="O3">
            <title>Rosiglitazone</title>
            <description>Rosiglitazone 2 mg BID for 4-weeks followed by rosiglitazone 4 mgs BID for 16-weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Ratio (Value at Endpoint Divided by Value at Baseline) of AUC for Insulin During a Meal Challenge Test (MCT).</title>
          <description>Ratio (value at endpoint divided by value at baseline) of AUC (15-180 min) for insulin (uIU-min/ml) during MCT.</description>
          <population>All patients in full analysis set who have both baseline and endpoint measurement.</population>
          <units>uIU-min/ml</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline AUC for insulin during MCT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5171.40" spread="522.82"/>
                    <measurement group_id="O2" value="4324.13" spread="430.87"/>
                    <measurement group_id="O3" value="5816.83" spread="596.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ratio(endpoint/baseline) of insulin AUC during MCT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.806" spread="0.063"/>
                    <measurement group_id="O2" value="0.664" spread="0.052"/>
                    <measurement group_id="O3" value="0.722" spread="0.058"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.465</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in AUC for C-peptide During a Meal Challenge Test (MCT).</title>
        <description>Ratio (value at endpoint divided by value at baseline) of AUC(15-180 min) for C-peptide (nmol-min/L) during a MCT from baseline to week 20.</description>
        <time_frame>Week 20</time_frame>
        <population>All patients in full analysis set who have both baseline and endpoint measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Exenatide</title>
            <description>Exenatide 5 mcg twice a day (BID) for 4-weeks followed by exenatide 10 mcg BID for 16-weeks.</description>
          </group>
          <group group_id="O2">
            <title>Exenatide Plus Rosiglitazone</title>
            <description>Exenatide 5 mcg BID + rosiglitazone 2 mg BID for 4-weeks followed by exenatide 10 mcg + rosiglitazone 4 mg BID for 16-weeks.</description>
          </group>
          <group group_id="O3">
            <title>Rosiglitazone</title>
            <description>Rosiglitazone 2 mg BID for 4-weeks followed by rosiglitazone 4 mgs BID for 16-weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in AUC for C-peptide During a Meal Challenge Test (MCT).</title>
          <description>Ratio (value at endpoint divided by value at baseline) of AUC(15-180 min) for C-peptide (nmol-min/L) during a MCT from baseline to week 20.</description>
          <population>All patients in full analysis set who have both baseline and endpoint measurement.</population>
          <units>nmol-min/L</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline C-peptide during a MCT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="319.77" spread="18.13"/>
                    <measurement group_id="O2" value="310.51" spread="17.61"/>
                    <measurement group_id="O3" value="325.65" spread="19.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ratio(endpoint/baseline) of C-peptide during a MCT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.908" spread="0.040"/>
                    <measurement group_id="O2" value="0.804" spread="0.036"/>
                    <measurement group_id="O3" value="0.854" spread="0.039"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.348</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Incremental for Postprandial Glucose During a Meal Challenge Test (MCT).</title>
        <description>Change in incremental for postprandial glucose (mmol/L) during a MCT from baseline to week 20.</description>
        <time_frame>Week 20</time_frame>
        <population>All patients in full analysis set who have both baseline and endpoint measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Exenatide</title>
            <description>Exenatide 5 mcg twice a day (BID) for 4-weeks followed by exenatide 10 mcg BID for 16-weeks.</description>
          </group>
          <group group_id="O2">
            <title>Exenatide Plus Rosiglitazone</title>
            <description>Exenatide 5 mcg BID + rosiglitazone 2 mg BID for 4-weeks followed by exenatide 10 mcg + rosiglitazone 4 mg BID for 16-weeks.</description>
          </group>
          <group group_id="O3">
            <title>Rosiglitazone</title>
            <description>Rosiglitazone 2 mg BID for 4-weeks followed by rosiglitazone 4 mgs BID for 16-weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Incremental for Postprandial Glucose During a Meal Challenge Test (MCT).</title>
          <description>Change in incremental for postprandial glucose (mmol/L) during a MCT from baseline to week 20.</description>
          <population>All patients in full analysis set who have both baseline and endpoint measurement.</population>
          <units>mmol/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline glucose at 15 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.950" spread="0.138"/>
                    <measurement group_id="O2" value="1.12" spread="0.138"/>
                    <measurement group_id="O3" value="0.828" spread="0.142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change fr baseline glucose at 15 min at wk 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.651" spread="0.151"/>
                    <measurement group_id="O2" value="-0.286" spread="0.152"/>
                    <measurement group_id="O3" value="0.150" spread="0.157"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline glucose at 30 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.39" spread="0.218"/>
                    <measurement group_id="O2" value="2.54" spread="0.221"/>
                    <measurement group_id="O3" value="2.23" spread="0.221"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change fr baseline glucose at 30 min at wk 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.46" spread="0.248"/>
                    <measurement group_id="O2" value="-1.06" spread="0.252"/>
                    <measurement group_id="O3" value="-0.066" spread="0.252"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline glucose at 60 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.59" spread="0.273"/>
                    <measurement group_id="O2" value="3.88" spread="0.273"/>
                    <measurement group_id="O3" value="3.48" spread="0.273"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change fr baseline glucose at 60 min at wk 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.56" spread="0.329"/>
                    <measurement group_id="O2" value="-2.46" spread="0.330"/>
                    <measurement group_id="O3" value="-0.720" spread="0.329"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline glucose at 90 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.24" spread="0.231"/>
                    <measurement group_id="O2" value="3.36" spread="0.228"/>
                    <measurement group_id="O3" value="3.48" spread="0.239"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change fr baseline glucose at 90 min at wk 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.87" spread="0.312"/>
                    <measurement group_id="O2" value="-2.91" spread="0.307"/>
                    <measurement group_id="O3" value="-0.952" spread="0.322"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline glucose at 120 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.49" spread="0.235"/>
                    <measurement group_id="O2" value="2.24" spread="0.238"/>
                    <measurement group_id="O3" value="2.31" spread="0.235"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change fr baseline glucose at 120 min at wk 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.24" spread="0.271"/>
                    <measurement group_id="O2" value="-2.52" spread="0.275"/>
                    <measurement group_id="O3" value="-0.912" spread="0.271"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline glucose at 150 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.62" spread="0.230"/>
                    <measurement group_id="O2" value="1.14" spread="0.230"/>
                    <measurement group_id="O3" value="1.25" spread="0.230"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change fr baseline glucose at 150 min at wk 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.42" spread="0.288"/>
                    <measurement group_id="O2" value="-1.95" spread="0.287"/>
                    <measurement group_id="O3" value="-0.830" spread="0.286"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline glucose at 180 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.461" spread="0.235"/>
                    <measurement group_id="O2" value="0.036" spread="0.235"/>
                    <measurement group_id="O3" value="0.279" spread="0.235"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change fr baseline glucose at 180 min at wk 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.583" spread="0.231"/>
                    <measurement group_id="O2" value="-0.995" spread="0.232"/>
                    <measurement group_id="O3" value="-0.481" spread="0.230"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Incremental for Postprandial Insulin During Meal Challenge Test (MCT).</title>
        <description>Change in incremental for postprandial insulin (mmol/L) during meal challenge test (MCT) from baseline to week 20.</description>
        <time_frame>Week 20</time_frame>
        <population>All patients in full analysis set who have both baseline and endpoint measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Exenatide</title>
            <description>Exenatide 5 mcg twice a day (BID) for 4-weeks followed by exenatide 10 mcg BID for 16-weeks.</description>
          </group>
          <group group_id="O2">
            <title>Exenatide Plus Rosiglitazone</title>
            <description>Exenatide 5 mcg BID + rosiglitazone 2 mg BID for 4-weeks followed by exenatide 10 mcg + rosiglitazone 4 mg BID for 16-weeks.</description>
          </group>
          <group group_id="O3">
            <title>Rosiglitazone</title>
            <description>Rosiglitazone 2 mg BID for 4-weeks followed by rosiglitazone 4 mgs BID for 16-weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Incremental for Postprandial Insulin During Meal Challenge Test (MCT).</title>
          <description>Change in incremental for postprandial insulin (mmol/L) during meal challenge test (MCT) from baseline to week 20.</description>
          <population>All patients in full analysis set who have both baseline and endpoint measurement.</population>
          <units>mmol/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline insulin at 15 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.97" spread="1.71"/>
                    <measurement group_id="O2" value="8.09" spread="1.71"/>
                    <measurement group_id="O3" value="7.53" spread="1.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change fr baseline insulin at 15 min at wk 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.71" spread="1.45"/>
                    <measurement group_id="O2" value="-1.84" spread="1.45"/>
                    <measurement group_id="O3" value="-0.455" spread="1.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline insulin at 30 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.81" spread="2.28"/>
                    <measurement group_id="O2" value="14.79" spread="2.25"/>
                    <measurement group_id="O3" value="18.83" spread="2.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change fr baseline insulin at 30 min at wk 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.00" spread="1.90"/>
                    <measurement group_id="O2" value="-2.63" spread="1.89"/>
                    <measurement group_id="O3" value="-1.04" spread="1.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline insulin at 60 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.92" spread="4.68"/>
                    <measurement group_id="O2" value="27.67" spread="4.61"/>
                    <measurement group_id="O3" value="32.09" spread="4.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change fr baseline insulin at 60 min at wk 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.04" spread="2.63"/>
                    <measurement group_id="O2" value="-7.47" spread="2.59"/>
                    <measurement group_id="O3" value="-7.42" spread="2.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline insulin at 90 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.06" spread="4.10"/>
                    <measurement group_id="O2" value="21.85" spread="4.10"/>
                    <measurement group_id="O3" value="32.25" spread="4.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change fr baseline insulin at 90 min at wk 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.42" spread="2.72"/>
                    <measurement group_id="O2" value="-9.27" spread="2.74"/>
                    <measurement group_id="O3" value="-6.19" spread="2.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline insulin at 120 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.56" spread="2.99"/>
                    <measurement group_id="O2" value="17.52" spread="2.99"/>
                    <measurement group_id="O3" value="25.47" spread="3.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change fr baseline insulin at 120 min at wk 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.26" spread="1.99"/>
                    <measurement group_id="O2" value="-8.69" spread="2.00"/>
                    <measurement group_id="O3" value="-6.43" spread="2.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline insulin at 150 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.67" spread="2.47"/>
                    <measurement group_id="O2" value="12.74" spread="2.43"/>
                    <measurement group_id="O3" value="18.11" spread="2.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change fr baseline insulin at 150 min at wk 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.48" spread="1.74"/>
                    <measurement group_id="O2" value="-8.13" spread="1.73"/>
                    <measurement group_id="O3" value="-5.57" spread="1.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline insulin at 180 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.58" spread="1.73"/>
                    <measurement group_id="O2" value="8.18" spread="1.73"/>
                    <measurement group_id="O3" value="10.74" spread="1.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change fr baseline insulin at 180 min at wk 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.031" spread="1.30"/>
                    <measurement group_id="O2" value="-5.26" spread="1.30"/>
                    <measurement group_id="O3" value="-4.04" spread="1.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Incremental for Postprandial C-peptide During Meal Challenge Test (MCT).</title>
        <description>Change in incremental for postprandial C-peptide (mmol/L) during MCT from baseline to week 20.</description>
        <time_frame>Week 20</time_frame>
        <population>All patients in full analysis set who have baseline and endpoint measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>Exenatide</title>
            <description>Exenatide 5 mcg twice a day (BID) for 4-weeks followed by exenatide 10 mcg BID for 16-weeks.</description>
          </group>
          <group group_id="O2">
            <title>Exenatide Plus Rosiglitazone</title>
            <description>Exenatide 5 mcg BID + rosiglitazone 2 mg BID for 4-weeks followed by exenatide 10 mcg + rosiglitazone 4 mg BID for 16-weeks.</description>
          </group>
          <group group_id="O3">
            <title>Rosiglitazone</title>
            <description>Rosiglitazone 2 mg BID for 4-weeks followed by rosiglitazone 4 mgs BID for 16-weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Incremental for Postprandial C-peptide During Meal Challenge Test (MCT).</title>
          <description>Change in incremental for postprandial C-peptide (mmol/L) during MCT from baseline to week 20.</description>
          <population>All patients in full analysis set who have baseline and endpoint measurement.</population>
          <units>mmol/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline C-peptide at 15 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.238" spread="0.049"/>
                    <measurement group_id="O2" value="0.259" spread="0.049"/>
                    <measurement group_id="O3" value="0.206" spread="0.051"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change fr baseline C-peptide at 15 min at week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.006" spread="0.045"/>
                    <measurement group_id="O2" value="0.016" spread="0.046"/>
                    <measurement group_id="O3" value="0.087" spread="0.047"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline C-peptide at 30 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.521" spread="0.059"/>
                    <measurement group_id="O2" value="0.517" spread="0.059"/>
                    <measurement group_id="O3" value="0.560" spread="0.061"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change fr baseline C-peptide at 30 min at week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.071" spread="0.056"/>
                    <measurement group_id="O2" value="-0.036" spread="0.056"/>
                    <measurement group_id="O3" value="0.099" spread="0.058"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline C-peptide at 60 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.818" spread="0.110"/>
                    <measurement group_id="O2" value="0.871" spread="0.110"/>
                    <measurement group_id="O3" value="0.881" spread="0.114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change fr baseline C-peptide at 60 min at week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.148" spread="0.090"/>
                    <measurement group_id="O2" value="-0.025" spread="0.090"/>
                    <measurement group_id="O3" value="0.054" spread="0.093"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline C-peptide at 90 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.895" spread="0.100"/>
                    <measurement group_id="O2" value="0.953" spread="0.101"/>
                    <measurement group_id="O3" value="1.03" spread="0.106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change fr baseline C-peptide at 90 min at week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.185" spread="0.099"/>
                    <measurement group_id="O2" value="-0.117" spread="0.101"/>
                    <measurement group_id="O3" value="-0.052" spread="0.106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline C-peptide at 120 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.817" spread="0.112"/>
                    <measurement group_id="O2" value="0.828" spread="0.114"/>
                    <measurement group_id="O3" value="0.972" spread="0.114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change fr baseline C-peptide at 120 min at week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.259" spread="0.100"/>
                    <measurement group_id="O2" value="-0.134" spread="0.102"/>
                    <measurement group_id="O3" value="-0.016" spread="0.102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline C-peptide at 150 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.843" spread="0.091"/>
                    <measurement group_id="O2" value="0.651" spread="0.091"/>
                    <measurement group_id="O3" value="0.813" spread="0.092"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change fr baseline C-peptide at 150 min at week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.251" spread="0.095"/>
                    <measurement group_id="O2" value="-0.254" spread="0.095"/>
                    <measurement group_id="O3" value="-0.093" spread="0.096"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline C-peptide at 180 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.610" spread="0.084"/>
                    <measurement group_id="O2" value="0.482" spread="0.085"/>
                    <measurement group_id="O3" value="0.619" spread="0.087"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change fr baseline C-peptide at 180 min at week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.075" spread="0.062"/>
                    <measurement group_id="O2" value="-0.238" spread="0.063"/>
                    <measurement group_id="O3" value="-0.092" spread="0.064"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in HbA1c</title>
        <description>Change in HbA1c from baseline to week 20.</description>
        <time_frame>Week 20</time_frame>
        <population>All patients who have both baseline and at least one post baseline value in full analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Exenatide</title>
            <description>Exenatide 5 mcg twice a day (BID) for 4-weeks followed by exenatide 10 mcg BID for 16-weeks.</description>
          </group>
          <group group_id="O2">
            <title>Exenatide Plus Rosiglitazone</title>
            <description>Exenatide 5 mcg BID + rosiglitazone 2 mg BID for 4-weeks followed by exenatide 10 mcg + rosiglitazone 4 mg BID for 16-weeks.</description>
          </group>
          <group group_id="O3">
            <title>Rosiglitazone</title>
            <description>Rosiglitazone 2 mg BID for 4-weeks followed by rosiglitazone 4 mgs BID for 16-weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in HbA1c</title>
          <description>Change in HbA1c from baseline to week 20.</description>
          <population>All patients who have both baseline and at least one post baseline value in full analysis set.</population>
          <units>Percentage</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline HbA1c</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.79" spread="0.116"/>
                    <measurement group_id="O2" value="7.84" spread="0.115"/>
                    <measurement group_id="O3" value="7.92" spread="0.116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline HbA1c at week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.908" spread="0.118"/>
                    <measurement group_id="O2" value="-1.31" spread="0.116"/>
                    <measurement group_id="O3" value="-0.968" spread="0.118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.039</p_value>
            <method>Mixed Model Repeated Measures (MMRM)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Fasting Serum Glucose Concentration.</title>
        <description>Change in fasting serum glucose concentration from baseline to week 20.</description>
        <time_frame>Week 20</time_frame>
        <population>All patients who have both baseline and at least one post baseline value in full analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Exenatide</title>
            <description>Exenatide 5 mcg twice a day (BID) for 4-weeks followed by exenatide 10 mcg BID for 16-weeks.</description>
          </group>
          <group group_id="O2">
            <title>Exenatide Plus Rosiglitazone</title>
            <description>Exenatide 5 mcg BID + rosiglitazone 2 mg BID for 4-weeks followed by exenatide 10 mcg + rosiglitazone 4 mg BID for 16-weeks.</description>
          </group>
          <group group_id="O3">
            <title>Rosiglitazone</title>
            <description>Rosiglitazone 2 mg BID for 4-weeks followed by rosiglitazone 4 mgs BID for 16-weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fasting Serum Glucose Concentration.</title>
          <description>Change in fasting serum glucose concentration from baseline to week 20.</description>
          <population>All patients who have both baseline and at least one post baseline value in full analysis set.</population>
          <units>mmol/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline fasting serum glucose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.42" spread="0.278"/>
                    <measurement group_id="O2" value="8.43" spread="0.271"/>
                    <measurement group_id="O3" value="8.48" spread="0.274"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change fr baseline fasting serum glucose at wk 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.46" spread="0.250"/>
                    <measurement group_id="O2" value="-1.60" spread="0.244"/>
                    <measurement group_id="O3" value="-1.80" spread="0.250"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.555</p_value>
            <method>MMRM</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Fasting C-peptide</title>
        <description>Change in fasting C-peptide from baseline to week 20.</description>
        <time_frame>Week 20</time_frame>
        <population>Fasting C-peptide was initially identified as an outcome measure, but data for this measure were not subsequently collected at baseline or endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Exenatide</title>
            <description>Exenatide 5 mcg twice a day (BID) for 4-weeks followed by exenatide 10 mcg BID for 16-weeks.</description>
          </group>
          <group group_id="O2">
            <title>Exenatide Plus Rosiglitazone</title>
            <description>Exenatide 5 mcg BID + rosiglitazone 2 mg BID for 4-weeks followed by exenatide 10 mcg + rosiglitazone 4 mg BID for 16-weeks.</description>
          </group>
          <group group_id="O3">
            <title>Rosiglitazone</title>
            <description>Rosiglitazone 2 mg BID for 4-weeks followed by rosiglitazone 4 mgs BID for 16-weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fasting C-peptide</title>
          <description>Change in fasting C-peptide from baseline to week 20.</description>
          <population>Fasting C-peptide was initially identified as an outcome measure, but data for this measure were not subsequently collected at baseline or endpoint.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Fasting Insulin</title>
        <description>Change in fasting insulin from baseline to week 20.</description>
        <time_frame>Week 20</time_frame>
        <population>All patients who have both baseline and at least one post baseline value in full analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Exenatide</title>
            <description>Exenatide 5 mcg twice a day (BID) for 4-weeks followed by exenatide 10 mcg BID for 16-weeks.</description>
          </group>
          <group group_id="O2">
            <title>Exenatide Plus Rosiglitazone</title>
            <description>Exenatide 5 mcg BID + rosiglitazone 2 mg BID for 4-weeks followed by exenatide 10 mcg + rosiglitazone 4 mg BID for 16-weeks.</description>
          </group>
          <group group_id="O3">
            <title>Rosiglitazone</title>
            <description>Rosiglitazone 2 mg BID for 4-weeks followed by rosiglitazone 4 mgs BID for 16-weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fasting Insulin</title>
          <description>Change in fasting insulin from baseline to week 20.</description>
          <population>All patients who have both baseline and at least one post baseline value in full analysis set.</population>
          <units>uIU/ml</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline fasting insulin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.84" spread="1.55"/>
                    <measurement group_id="O2" value="10.96" spread="1.33"/>
                    <measurement group_id="O3" value="12.77" spread="1.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ratio (wk20/baseline)of fasting insulin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.980" spread="0.096"/>
                    <measurement group_id="O2" value="0.599" spread="0.059"/>
                    <measurement group_id="O3" value="0.755" spread="0.078"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.106</p_value>
            <method>MMRM</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Fasting Proinsulin</title>
        <description>Ratio (endpoint value divided by baseline value) for fasting proinsulin, comparing endpoint (week 20) to baseline</description>
        <time_frame>Week 20</time_frame>
        <population>All patients who have both baseline and at least one post baseline value in full analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Exenatide</title>
            <description>Exenatide 5 mcg twice a day (BID) for 4-weeks followed by exenatide 10 mcg BID for 16-weeks.</description>
          </group>
          <group group_id="O2">
            <title>Exenatide Plus Rosiglitazone</title>
            <description>Exenatide 5 mcg BID + rosiglitazone 2 mg BID for 4-weeks followed by exenatide 10 mcg + rosiglitazone 4 mg BID for 16-weeks.</description>
          </group>
          <group group_id="O3">
            <title>Rosiglitazone</title>
            <description>Rosiglitazone 2 mg BID for 4-weeks followed by rosiglitazone 4 mgs BID for 16-weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fasting Proinsulin</title>
          <description>Ratio (endpoint value divided by baseline value) for fasting proinsulin, comparing endpoint (week 20) to baseline</description>
          <population>All patients who have both baseline and at least one post baseline value in full analysis set.</population>
          <units>pmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline fasting proinsulin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.32" spread="0.523"/>
                    <measurement group_id="O2" value="3.80" spread="0.455"/>
                    <measurement group_id="O3" value="3.56" spread="0.423"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ratio(wk20/baseline)of fasting proinsulin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.663" spread="0.073"/>
                    <measurement group_id="O2" value="0.538" spread="0.058"/>
                    <measurement group_id="O3" value="0.623" spread="0.068"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.341</p_value>
            <method>MMRM</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Body Weight</title>
        <description>Change in body weight from baseline to week 20.</description>
        <time_frame>Week 20</time_frame>
        <population>All patients who aave both baseline and at least one post baseline value in full analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Exenatide</title>
            <description>Exenatide 5 mcg twice a day (BID) for 4-weeks followed by exenatide 10 mcg BID for 16-weeks.</description>
          </group>
          <group group_id="O2">
            <title>Exenatide Plus Rosiglitazone</title>
            <description>Exenatide 5 mcg BID + rosiglitazone 2 mg BID for 4-weeks followed by exenatide 10 mcg + rosiglitazone 4 mg BID for 16-weeks.</description>
          </group>
          <group group_id="O3">
            <title>Rosiglitazone</title>
            <description>Rosiglitazone 2 mg BID for 4-weeks followed by rosiglitazone 4 mgs BID for 16-weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Body Weight</title>
          <description>Change in body weight from baseline to week 20.</description>
          <population>All patients who aave both baseline and at least one post baseline value in full analysis set.</population>
          <units>kg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline body weight</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.05" spread="2.39"/>
                    <measurement group_id="O2" value="93.76" spread="2.36"/>
                    <measurement group_id="O3" value="91.78" spread="2.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in body weight at week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.82" spread="0.547"/>
                    <measurement group_id="O2" value="-1.21" spread="0.538"/>
                    <measurement group_id="O3" value="1.48" spread="0.547"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>MMRM</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Fasting Total Cholesterol.</title>
        <description>Change in fasting total cholestrol from baseline to week 20.</description>
        <time_frame>Week 20</time_frame>
        <population>All patients who have both baseline and at least one post baseline value in full analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Exenatide</title>
            <description>Exenatide 5 mcg twice a day (BID) for 4-weeks followed by exenatide 10 mcg BID for 16-weeks.</description>
          </group>
          <group group_id="O2">
            <title>Exenatide Plus Rosiglitazone</title>
            <description>Exenatide 5 mcg BID + rosiglitazone 2 mg BID for 4-weeks followed by exenatide 10 mcg + rosiglitazone 4 mg BID for 16-weeks.</description>
          </group>
          <group group_id="O3">
            <title>Rosiglitazone</title>
            <description>Rosiglitazone 2 mg BID for 4-weeks followed by rosiglitazone 4 mgs BID for 16-weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fasting Total Cholesterol.</title>
          <description>Change in fasting total cholestrol from baseline to week 20.</description>
          <population>All patients who have both baseline and at least one post baseline value in full analysis set.</population>
          <units>mmol/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline total cholesterol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.42" spread="0.150"/>
                    <measurement group_id="O2" value="4.41" spread="0.145"/>
                    <measurement group_id="O3" value="4.62" spread="0.149"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change fr baseline total cholesterol at week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.128" spread="0.118"/>
                    <measurement group_id="O2" value="0.258" spread="0.114"/>
                    <measurement group_id="O3" value="0.438" spread="0.118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.276</p_value>
            <method>MMRM</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Fasting HDL Cholesterol</title>
        <description>Change in fasting high-density lipoprotein (HDL) cholesterol from baseline to week 20.</description>
        <time_frame>Week 20</time_frame>
        <population>All patients who have both baseline and at least one post baseline value in full analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Exenatide</title>
            <description>Exenatide 5 mcg twice a day (BID) for 4-weeks followed by exenatide 10 mcg BID for 16-weeks.</description>
          </group>
          <group group_id="O2">
            <title>Exenatide Plus Rosiglitazone</title>
            <description>Exenatide 5 mcg BID + rosiglitazone 2 mg BID for 4-weeks followed by exenatide 10 mcg + rosiglitazone 4 mg BID for 16-weeks.</description>
          </group>
          <group group_id="O3">
            <title>Rosiglitazone</title>
            <description>Rosiglitazone 2 mg BID for 4-weeks followed by rosiglitazone 4 mgs BID for 16-weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fasting HDL Cholesterol</title>
          <description>Change in fasting high-density lipoprotein (HDL) cholesterol from baseline to week 20.</description>
          <population>All patients who have both baseline and at least one post baseline value in full analysis set.</population>
          <units>mmol/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline HDL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.13" spread="0.048"/>
                    <measurement group_id="O2" value="1.17" spread="0.047"/>
                    <measurement group_id="O3" value="1.17" spread="0.048"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline HDL at week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.022" spread="0.030"/>
                    <measurement group_id="O2" value="0.046" spread="0.029"/>
                    <measurement group_id="O3" value="0.055" spread="0.030"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.840</p_value>
            <method>MMRM</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Fasting LDL Cholesterol</title>
        <description>Change in fasting low-density lipoprotein (LDL) cholesterol from baseline to week 20.</description>
        <time_frame>Week 20</time_frame>
        <population>All patients who have both baseline and at least one post baseline value in full analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Exenatide</title>
            <description>Exenatide 5 mcg twice a day (BID) for 4-weeks followed by exenatide 10 mcg BID for 16-weeks.</description>
          </group>
          <group group_id="O2">
            <title>Exenatide Plus Rosiglitazone</title>
            <description>Exenatide 5 mcg BID + rosiglitazone 2 mg BID for 4-weeks followed by exenatide 10 mcg + rosiglitazone 4 mg BID for 16-weeks.</description>
          </group>
          <group group_id="O3">
            <title>Rosiglitazone</title>
            <description>Rosiglitazone 2 mg BID for 4-weeks followed by rosiglitazone 4 mgs BID for 16-weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fasting LDL Cholesterol</title>
          <description>Change in fasting low-density lipoprotein (LDL) cholesterol from baseline to week 20.</description>
          <population>All patients who have both baseline and at least one post baseline value in full analysis set.</population>
          <units>mmol/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline LDL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.59" spread="0.131"/>
                    <measurement group_id="O2" value="2.57" spread="0.128"/>
                    <measurement group_id="O3" value="2.71" spread="0.129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline LDL at week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.049" spread="0.102"/>
                    <measurement group_id="O2" value="0.096" spread="0.100"/>
                    <measurement group_id="O3" value="0.334" spread="0.101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.096</p_value>
            <method>MMRM</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Fasting Triglycerides</title>
        <description>Ratio (endpint value divided by baseline value) of fasting triglycerides from baseline to week 20.</description>
        <time_frame>Week 20</time_frame>
        <population>All patients who have both baseline and at least one post baseline value in full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Exenatide</title>
            <description>Exenatide 5 mcg twice a day (BID) for 4-weeks followed by exenatide 10 mcg BID for 16-weeks.</description>
          </group>
          <group group_id="O2">
            <title>Exenatide Plus Rosiglitazone</title>
            <description>Exenatide 5 mcg BID + rosiglitazone 2 mg BID for 4-weeks followed by exenatide 10 mcg + rosiglitazone 4 mg BID for 16-weeks.</description>
          </group>
          <group group_id="O3">
            <title>Rosiglitazone</title>
            <description>Rosiglitazone 2 mg BID for 4-weeks followed by rosiglitazone 4 mgs BID for 16-weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fasting Triglycerides</title>
          <description>Ratio (endpint value divided by baseline value) of fasting triglycerides from baseline to week 20.</description>
          <population>All patients who have both baseline and at least one post baseline value in full analysis set</population>
          <units>mmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline triglyceride</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.56" spread="0.124"/>
                    <measurement group_id="O2" value="1.67" spread="0.128"/>
                    <measurement group_id="O3" value="1.76" spread="0.138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ratio (endpoint/baseline) for triglycerides</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.861" spread="0.060"/>
                    <measurement group_id="O2" value="0.977" spread="0.066"/>
                    <measurement group_id="O3" value="0.992" spread="0.069"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.875</p_value>
            <method>MMRM</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Percent Body Fat During a Meal Challenge Test (MCT)</title>
        <description>Change in percent body fat from baseline to week 20, as assessed during an MCT</description>
        <time_frame>20 weeks</time_frame>
        <population>All Patients in Full Analysis Set Who Have Both Baseline and Endpoint Measurement</population>
        <group_list>
          <group group_id="O1">
            <title>Exenatide</title>
            <description>Exenatide 5 mcg twice a day (BID) for 4-weeks followed by exenatide 10 mcg BID for 16-weeks.</description>
          </group>
          <group group_id="O2">
            <title>Exenatide Plus Rosiglitazone</title>
            <description>Exenatide 5 mcg BID + rosiglitazone 2 mg BID for 4-weeks followed by exenatide 10 mcg + rosiglitazone 4 mg BID for 16-weeks.</description>
          </group>
          <group group_id="O3">
            <title>Rosiglitazone</title>
            <description>Rosiglitazone 2 mg BID for 4-weeks followed by rosiglitazone 4 mgs BID for 16-weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Percent Body Fat During a Meal Challenge Test (MCT)</title>
          <description>Change in percent body fat from baseline to week 20, as assessed during an MCT</description>
          <population>All Patients in Full Analysis Set Who Have Both Baseline and Endpoint Measurement</population>
          <units>percentage</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline percent body fat</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.42" spread="1.16"/>
                    <measurement group_id="O2" value="34.07" spread="1.15"/>
                    <measurement group_id="O3" value="32.50" spread="1.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in percent body fat at week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.40" spread="1.06"/>
                    <measurement group_id="O2" value="-0.347" spread="1.04"/>
                    <measurement group_id="O3" value="-1.18" spread="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.581</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Body Fat Mass During a Meal Challenge Test (MCT)</title>
        <description>Change in body fat mass form baseline to week 20, as assessed during an MCT</description>
        <time_frame>20 weeks</time_frame>
        <population>All Patients in Full Analysis Set Who Have Both Baseline and Endpoint Measurements</population>
        <group_list>
          <group group_id="O1">
            <title>Exenatide</title>
            <description>Exenatide 5 mcg twice a day (BID) for 4-weeks followed by exenatide 10 mcg BID for 16-weeks.</description>
          </group>
          <group group_id="O2">
            <title>Exenatide Plus Rosiglitazone</title>
            <description>Exenatide 5 mcg BID + rosiglitazone 2 mg BID for 4-weeks followed by exenatide 10 mcg + rosiglitazone 4 mg BID for 16-weeks.</description>
          </group>
          <group group_id="O3">
            <title>Rosiglitazone</title>
            <description>Rosiglitazone 2 mg BID for 4-weeks followed by rosiglitazone 4 mgs BID for 16-weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Body Fat Mass During a Meal Challenge Test (MCT)</title>
          <description>Change in body fat mass form baseline to week 20, as assessed during an MCT</description>
          <population>All Patients in Full Analysis Set Who Have Both Baseline and Endpoint Measurements</population>
          <units>kg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline body fat mass</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.05" spread="1.64"/>
                    <measurement group_id="O2" value="32.55" spread="1.62"/>
                    <measurement group_id="O3" value="30.54" spread="1.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in body fat mass at week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.76" spread="1.37"/>
                    <measurement group_id="O2" value="-1.06" spread="1.35"/>
                    <measurement group_id="O3" value="-1.99" spread="1.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.631</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Lean Body Mass During a Meal Challenge Test (MCT)</title>
        <description>Change in lean body mass from baseline to week 20, as assessed during an MCT</description>
        <time_frame>20 weeks</time_frame>
        <population>All Patients in Full Analysis Set Who Have Both Baseline and Endpoint Measurements</population>
        <group_list>
          <group group_id="O1">
            <title>Exenatide</title>
            <description>Exenatide 5 mcg twice a day (BID) for 4-weeks followed by exenatide 10 mcg BID for 16-weeks.</description>
          </group>
          <group group_id="O2">
            <title>Exenatide Plus Rosiglitazone</title>
            <description>Exenatide 5 mcg BID + rosiglitazone 2 mg BID for 4-weeks followed by exenatide 10 mcg + rosiglitazone 4 mg BID for 16-weeks.</description>
          </group>
          <group group_id="O3">
            <title>Rosiglitazone</title>
            <description>Rosiglitazone 2 mg BID for 4-weeks followed by rosiglitazone 4 mgs BID for 16-weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Lean Body Mass During a Meal Challenge Test (MCT)</title>
          <description>Change in lean body mass from baseline to week 20, as assessed during an MCT</description>
          <population>All Patients in Full Analysis Set Who Have Both Baseline and Endpoint Measurements</population>
          <units>kg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline lean body mass</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.62" spread="2.11"/>
                    <measurement group_id="O2" value="60.94" spread="2.08"/>
                    <measurement group_id="O3" value="61.09" spread="2.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in lean body mass at week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.99" spread="1.39"/>
                    <measurement group_id="O2" value="0.532" spread="1.37"/>
                    <measurement group_id="O3" value="1.23" spread="1.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.724</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Waist Circumference</title>
        <description>Change in waist circumference from baseline to week 20</description>
        <time_frame>20 weeks</time_frame>
        <population>All Patients Who Have Both Baseline and At Least One Post Baseline Value in Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Exenatide</title>
            <description>Exenatide 5 mcg twice a day (BID) for 4-weeks followed by exenatide 10 mcg BID for 16-weeks.</description>
          </group>
          <group group_id="O2">
            <title>Exenatide Plus Rosiglitazone</title>
            <description>Exenatide 5 mcg BID + rosiglitazone 2 mg BID for 4-weeks followed by exenatide 10 mcg + rosiglitazone 4 mg BID for 16-weeks.</description>
          </group>
          <group group_id="O3">
            <title>Rosiglitazone</title>
            <description>Rosiglitazone 2 mg BID for 4-weeks followed by rosiglitazone 4 mgs BID for 16-weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Waist Circumference</title>
          <description>Change in waist circumference from baseline to week 20</description>
          <population>All Patients Who Have Both Baseline and At Least One Post Baseline Value in Full Analysis Set</population>
          <units>cm</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline waist circumference</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105.98" spread="1.68"/>
                    <measurement group_id="O2" value="106.85" spread="1.67"/>
                    <measurement group_id="O3" value="105.34" spread="1.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in waist circumference at Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.95" spread="0.975"/>
                    <measurement group_id="O2" value="-2.38" spread="0.955"/>
                    <measurement group_id="O3" value="-0.225" spread="0.969"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.117</p_value>
            <method>MMRM</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Hip Circumference</title>
        <description>Change in hip circumference form baseline to week 20</description>
        <time_frame>20 weeks</time_frame>
        <population>All Patients Who Have Both Baseline and At Least One Post Baseline Value in Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Exenatide</title>
            <description>Exenatide 5 mcg twice a day (BID) for 4-weeks followed by exenatide 10 mcg BID for 16-weeks.</description>
          </group>
          <group group_id="O2">
            <title>Exenatide Plus Rosiglitazone</title>
            <description>Exenatide 5 mcg BID + rosiglitazone 2 mg BID for 4-weeks followed by exenatide 10 mcg + rosiglitazone 4 mg BID for 16-weeks.</description>
          </group>
          <group group_id="O3">
            <title>Rosiglitazone</title>
            <description>Rosiglitazone 2 mg BID for 4-weeks followed by rosiglitazone 4 mgs BID for 16-weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Hip Circumference</title>
          <description>Change in hip circumference form baseline to week 20</description>
          <population>All Patients Who Have Both Baseline and At Least One Post Baseline Value in Full Analysis Set</population>
          <units>cm</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline hip circumference</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113.29" spread="1.71"/>
                    <measurement group_id="O2" value="112.12" spread="1.69"/>
                    <measurement group_id="O3" value="111.90" spread="1.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in hip circumference at week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.28" spread="0.848"/>
                    <measurement group_id="O2" value="0.147" spread="0.827"/>
                    <measurement group_id="O3" value="1.51" spread="0.838"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.251</p_value>
            <method>MMRM</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Waist-to-hip Ratio</title>
        <description>Change in waist-to-hip ratio (waist circumference divided by hip circumference) from baseline to week 20</description>
        <time_frame>20 weeks</time_frame>
        <population>All Patients Who Have Both Baseline and At Least One Post Baseline Value in Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Exenatide</title>
            <description>Exenatide 5 mcg twice a day (BID) for 4-weeks followed by exenatide 10 mcg BID for 16-weeks.</description>
          </group>
          <group group_id="O2">
            <title>Exenatide Plus Rosiglitazone</title>
            <description>Exenatide 5 mcg BID + rosiglitazone 2 mg BID for 4-weeks followed by exenatide 10 mcg + rosiglitazone 4 mg BID for 16-weeks.</description>
          </group>
          <group group_id="O3">
            <title>Rosiglitazone</title>
            <description>Rosiglitazone 2 mg BID for 4-weeks followed by rosiglitazone 4 mgs BID for 16-weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Waist-to-hip Ratio</title>
          <description>Change in waist-to-hip ratio (waist circumference divided by hip circumference) from baseline to week 20</description>
          <population>All Patients Who Have Both Baseline and At Least One Post Baseline Value in Full Analysis Set</population>
          <units>ratio (cm/cm)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline waist-to-hip ratio</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.939" spread="0.012"/>
                    <measurement group_id="O2" value="0.957" spread="0.012"/>
                    <measurement group_id="O3" value="0.943" spread="0.012"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in waist-to-hip ratio at week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.016" spread="0.011"/>
                    <measurement group_id="O2" value="-0.022" spread="0.010"/>
                    <measurement group_id="O3" value="-0.016" spread="0.011"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.710</p_value>
            <method>MMRM</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Hypoglycemia Events</title>
        <description>Number of subjects experiencing hypoglycemia at any point during the study</description>
        <time_frame>20 weeks</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Exenatide</title>
            <description>Exenatide 5 mcg twice a day (BID) for 4-weeks followed by exenatide 10 mcg BID for 16-weeks.</description>
          </group>
          <group group_id="O2">
            <title>Exenatide Plus Rosiglitazone</title>
            <description>Exenatide 5 mcg BID + rosiglitazone 2 mg BID for 4-weeks followed by exenatide 10 mcg + rosiglitazone 4 mg BID for 16-weeks.</description>
          </group>
          <group group_id="O3">
            <title>Rosiglitazone</title>
            <description>Rosiglitazone 2 mg BID for 4-weeks followed by rosiglitazone 4 mgs BID for 16-weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Hypoglycemia Events</title>
          <description>Number of subjects experiencing hypoglycemia at any point during the study</description>
          <population>Full Analysis Set</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.575</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hypoglycemia Rate Per 30 Days Per Patient</title>
        <description>Average number of episodes of hypoglycemia per 30 days per patient</description>
        <time_frame>20 weeks</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Exenatide</title>
            <description>Exenatide 5 mcg twice a day (BID) for 4-weeks followed by exenatide 10 mcg BID for 16-weeks.</description>
          </group>
          <group group_id="O2">
            <title>Exenatide Plus Rosiglitazone</title>
            <description>Exenatide 5 mcg BID + rosiglitazone 2 mg BID for 4-weeks followed by exenatide 10 mcg + rosiglitazone 4 mg BID for 16-weeks.</description>
          </group>
          <group group_id="O3">
            <title>Rosiglitazone</title>
            <description>Rosiglitazone 2 mg BID for 4-weeks followed by rosiglitazone 4 mgs BID for 16-weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Hypoglycemia Rate Per 30 Days Per Patient</title>
          <description>Average number of episodes of hypoglycemia per 30 days per patient</description>
          <population>Full Analysis Set</population>
          <units>hypoglycemia events / 30 days / patient</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="47"/>
                <count group_id="O3" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.391" spread="0.298"/>
                    <measurement group_id="O2" value="0.594" spread="0.436"/>
                    <measurement group_id="O3" value="0.853" spread="1.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.436</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pedal Edema Score</title>
        <description>Pedal edema scores experienced by each patient throughout the study (&quot;1+&quot; indicates a patient experienced a pedal edema score of 1 , 2, or 3; &quot;2+&quot; indicates a patient experienced a pedal edema score of 2 or 3, etc.)
Scale:
Slight pitting, no visible distortion, disappears rapidly
A somewhat deeper pit than in 1+, but again no readily detectable distortion, and it disappears in 10 – 15 seconds
The pit is noticeably deep and may last more than a minute; the dependent extremity looks fuller and swollen
The pit is very deep, lasts as long as 2 – 5 minutes, and the dependent extremity is grossly distorted</description>
        <time_frame>20 weeks</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Exenatide</title>
            <description>Exenatide 5 mcg twice a day (BID) for 4-weeks followed by exenatide 10 mcg BID for 16-weeks.</description>
          </group>
          <group group_id="O2">
            <title>Exenatide Plus Rosiglitazone</title>
            <description>Exenatide 5 mcg BID + rosiglitazone 2 mg BID for 4-weeks followed by exenatide 10 mcg + rosiglitazone 4 mg BID for 16-weeks.</description>
          </group>
          <group group_id="O3">
            <title>Rosiglitazone</title>
            <description>Rosiglitazone 2 mg BID for 4-weeks followed by rosiglitazone 4 mgs BID for 16-weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Pedal Edema Score</title>
          <description>Pedal edema scores experienced by each patient throughout the study (&quot;1+&quot; indicates a patient experienced a pedal edema score of 1 , 2, or 3; &quot;2+&quot; indicates a patient experienced a pedal edema score of 2 or 3, etc.)
Scale:
Slight pitting, no visible distortion, disappears rapidly
A somewhat deeper pit than in 1+, but again no readily detectable distortion, and it disappears in 10 – 15 seconds
The pit is noticeably deep and may last more than a minute; the dependent extremity looks fuller and swollen
The pit is very deep, lasts as long as 2 – 5 minutes, and the dependent extremity is grossly distorted</description>
          <population>Full Analysis Set</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No edema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Edema score: 1+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Edema score: 2+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Edema score: 3+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.168</p_value>
            <method>Generalized Linear Model</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Exenatide</title>
          <description>Exenatide 5 mcg twice a day (BID) for 4-weeks followed by exenatide 10 mcg BID for 16-weeks.</description>
        </group>
        <group group_id="E2">
          <title>Exenatide Plus Rosiglitazone</title>
          <description>Exenatide 5 mcg BID + rosiglitazone 2 mg BID for 4-weeks followed by exenatide 10 mcg + rosiglitazone 4 mg BID for 16-weeks.</description>
        </group>
        <group group_id="E3">
          <title>Rosiglitazone</title>
          <description>Rosiglitazone 2 mg BID for 4-weeks followed by rosiglitazone 4 mgs BID for 16-weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3"/>
                <counts group_id="E2" subjects_affected="4"/>
                <counts group_id="E3" subjects_affected="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Helicobacter gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="35"/>
                <counts group_id="E2" subjects_affected="41"/>
                <counts group_id="E3" subjects_affected="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Injection site bruising</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Hunger</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Peter Ohman, Medical Science Director</name_or_title>
      <organization>AstraZeneca</organization>
      <email>ClinicalTrialTransparency@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

